<DOC>
	<DOC>NCT00859482</DOC>
	<brief_summary>Natalizumab is a humanized monoclonal antibody directed against Very Late Activation Antigene 4 (VLA-4) and has a potent effect on disease activity in multiple sclerosis (MS). A blockade of VLA-4 with natalizumab may not only interfere with autoimmunological processes but also with central nervous system (CNS) immune surveillance.</brief_summary>
	<brief_title>Differential Immune Effects of Natalizumab</brief_title>
	<detailed_description>Longitudinal ex vivo and in vitro study to determine the effect of natalizumab on frequency of distinct immune cells and on the frequency and suppressive function of natural CD4+CD25+ regulatory T cells (Tregs).</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>relapsing remitting MS indication for natalizumab treatment other disease modifying agents within 2 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>natalizumab</keyword>
	<keyword>multiple sclerosis</keyword>
</DOC>